Pfizer Korea's Plunazol-related claim for damage is unlikely to affect Daewoong Pharm

Hanyang Securities Co. said that Pfizer Korea submitted to Seoul District Court its claim for damage against patent infringement of Daewoong Pharm over Plunazol, which annualized domestic sales of 23.8 billion won last year and the third trial to confirm the scope of Pfizer's Plunazol patent right is now underway.

In the first trial on March 7, 2002, Pfizer Korea sued Daewoong Pharm for 100 ...